Search Results

RespireRx Pharmaceuticals Inc. is delighted to announce that the Department of Defense (DOD) has approved a $1.8 million translational research award to Shirley Ryan AbilityLab to fund a two stage Phase 2A and 2B clinical study.

RespireRx Pharmaceuticals Inc. is pleased to announce the appointment of Dr. Dariusz Nasiek MD, MBA to its board of directors.

RespireRx Pharmaceuticals Inc. is pleased to announce that, on December 6, 2023, it has entered into an agreement with Ponto Ventures LLC providing for Will Clodfelter to serve as RespireRx’s Senior Vice President of Business Development on a part-time basis.

RespireRx Pharmaceuticals Inc. is pleased to announce that KRM-II-81, its lead GABA A receptor potentiator (GABAkine), has advanced to the next level of evaluation within the NIH HEAL Initiative ® Preclinical Screening Platform for Pain.

RespireRx Pharmaceuticals Inc. is pleased to announce that, as part of an ongoing collaboration, a scientist team led by Dr. David Fuller of the University of Florida has published a peer-reviewed research article describing the ability of CX1739.

RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”) is pleased to announce the publication of a case report in Heliyon, Cell Press’s peer-reviewed journal (available at https://www.cell.com/heliyon/pdf/S2405-8440(23)10960-1.pdf) involving a 19-year old patient with pharmaco-resistant epilepsy.

RespireRx Pharmaceuticals Inc. are pleased to announce that on October 9, 2023, ResolutionRx entered into a Master Services Agreement (“MSA”) with Ab Initio Pharma Pty Ltd.

RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd, an unlisted public Australian company, and a subsidiary of RespireRx are pleased to jointly announce that on August 3, 2023, the Companies have entered into a series of bilateral agreements intended to transfer the RespireRx pharmaceutical cannabinoid program to ResolutionRx and establish it as an operating company.

RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd, collectively “RespireRx” and its subsidiaries and business units are referred to in this press release as the “Company.”

RespireRx Pharmaceuticals Inc. (OTC: RSPI) (“RespireRx” or the “Company”) is pleased to announce that on March 22, 2023, Mr. Joseph Siegelbaum was appointed to the Board of Directors as an independent director.